Lignocaine Viscous Syrup Dosing and Safety Guidelines

Dosing Limits and Toxicity Thresholds

The FDA‑approved labeling limits the single dose of 2 % lignocaine viscous solution to ≤4.5 mg/kg or 300 mg total (whichever is lower) to avoid systemic absorption that can cause cardiac and neurological toxicity when serum concentrations exceed 5 mg/L. 1
Cardiovascular toxicity may also occur when the topical dose exceeds 7 mg/kg, in addition to serum levels >5 mg/L. 1

In infants younger than 6 months, the maximum recommended dose is reduced to 4 mg/kg because of immature hepatic metabolism and a markedly prolonged elimination half‑life. 2
For underweight children, dosing should be calculated on ideal body weight rather than actual weight to prevent overdose. 2
Patients with hepatic impairment should receive lower doses due to reduced drug clearance and heightened toxicity risk. 1
Individuals with congestive heart failure require heightened caution because they are more susceptible to cardiac toxicity from lignocaine. 1

Children weighing less than 10 kg should be given 1 % or 2 % lignocaine solutions to achieve the needed volume while staying within safe dose limits. 2
Lignocaine solutions with concentrations greater than 4 % must never be used in pediatric patients. 2

Early neurological warning signs include circumoral numbness, facial tingling, metallic taste, dizziness, and euphoria; these should be actively monitored after administration. 1
Patients should be observed for at least 30–60 minutes following topical application, as systemic absorption may manifest later, although mucosal effects often resolve sooner. 2
Documentation of the exact lignocaine dose administered in the medical record is essential for safety tracking. 2

Concurrent use of other lignocaine‑containing products (e.g., sprays, gels) should be avoided during the same treatment period to prevent additive dosing. 3
Total daily lignocaine exposure across all routes and formulations must be tracked to ensure cumulative limits are not exceeded. 3

After topical airway anesthesia, patients should remain nil per os for a minimum of 1 hour; those at high aspiration risk may require a longer fasting interval. 2
The anesthetic effect typically lasts 30–60 minutes, with oral mucosal numbness possibly lasting less than 15 minutes; patients should remain under observation in a recovery area until the effect has worn off. 2
The elimination half‑life of lignocaine is 90–120 minutes in healthy adults and older children, but it is prolonged in infants under 6 months and in patients with hepatic dysfunction. 2